Tags

Type your tag names separated by a space and hit enter

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.
J Korean Med Sci. 2010 Nov; 25(11):1601-8.JK

Abstract

The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.

Authors+Show Affiliations

Cardiovascular Center, Seoul St. Mary's Hospital, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21060749

Citation

Cho, Jung Sun, et al. "Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With Glycoprotein IIb/IIIa Inhibitor." Journal of Korean Medical Science, vol. 25, no. 11, 2010, pp. 1601-8.
Cho JS, Her SH, Baek JY, et al. Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. J Korean Med Sci. 2010;25(11):1601-8.
Cho, J. S., Her, S. H., Baek, J. Y., Park, M. W., Kim, H. D., Jeong, M. H., Ahn, Y. k., Chae, S. C., Hur, S. H., Hong, T. J., Kim, Y. J., Seong, I. W., Chae, J. K., Rhew, J. Y., Chae, I. H., Cho, M. C., Bae, J. H., Rha, S. W., Kim, C. J., ... Park, S. J. (2010). Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. Journal of Korean Medical Science, 25(11), 1601-8. https://doi.org/10.3346/jkms.2010.25.11.1601
Cho JS, et al. Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With Glycoprotein IIb/IIIa Inhibitor. J Korean Med Sci. 2010;25(11):1601-8. PubMed PMID: 21060749.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. AU - Cho,Jung Sun, AU - Her,Sung-Ho, AU - Baek,Ju Yeal, AU - Park,Mahn-Won, AU - Kim,Hyoung Doo, AU - Jeong,Myung Ho, AU - Ahn,Young keun, AU - Chae,Shung Chull, AU - Hur,Seung Ho, AU - Hong,Taek Jong, AU - Kim,Young Jo, AU - Seong,In Whan, AU - Chae,Jei Keon, AU - Rhew,Jay Young, AU - Chae,In Ho, AU - Cho,Myeong Chan, AU - Bae,Jang Ho, AU - Rha,Seung Woon, AU - Kim,Chong Jim, AU - Choi,Donghoon, AU - Jang,Yang Soo, AU - Yoon,Junghan, AU - Chung,Wook Sung, AU - Cho,Jeong Gwan, AU - Seung,Ki Bae, AU - Park,Seung Jung, AU - ,, Y1 - 2010/10/26/ PY - 2010/05/04/received PY - 2010/06/16/accepted PY - 2010/11/10/entrez PY - 2010/11/10/pubmed PY - 2011/4/8/medline KW - Blood Platelets KW - Heparin KW - Myocardial Infarction KW - Prognosis SP - 1601 EP - 8 JF - Journal of Korean medical science JO - J Korean Med Sci VL - 25 IS - 11 N2 - The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH. SN - 1598-6357 UR - https://www.unboundmedicine.com/medline/citation/21060749/Clinical_benefit_of_low_molecular_weight_heparin_for_ST_segment_elevation_myocardial_infarction_patients_undergoing_primary_percutaneous_coronary_intervention_with_glycoprotein_IIb/IIIa_inhibitor_ L2 - https://jkms.org/DOIx.php?id=10.3346/jkms.2010.25.11.1601 DB - PRIME DP - Unbound Medicine ER -